Cloxacillin

CHEMBL891 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

435.9 g/mol

LogP

2.4

Phase

4

A penicillinase-resistant penicillin antibiotic used to treat infections caused by staphylococci that produce beta-lactamase enzymes. It works by inhibiting bacterial cell wall synthesis and is taken orally on an empty stomach for best absorption.

Peso molecular

435,9000 g/mol

LogP

2,40

TPSA

138,00 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Dermatitis atópica Enfermedad infecciosa Enfermedad renal crónica

Mecanismo de acción

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O

InChI

InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1

Molecular Formula

C19H18ClN3O5S

HBD / HBA

2 / 7

Enlaces Rotables

4

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A penicillinase-resistant penicillin antibiotic used to treat infections caused by staphylococci that produce beta-lactamase enzymes. It works by inhibiting bacterial cell wall synthesis and is taken orally on an empty stomach for best absorption.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Cloxacillin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL891. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6098. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Cloxacillin en PillFYI

Estructura

Datos Rápidos

Fórmula: C19H18ClN3O5S
Sinónimos: 2

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.